The NULISAseq™ Immune 340 Panel measures simultaneously – spanning innate and adaptive immunity, cytokines, chemokines, checkpoints, and cell-death pathways, with attomolar sensitivity and broad dynamic range that resolves low-abundance mediators alongside more abundant ones – all from a single 25 µL sample of plasma or serum. With attomolar sensitivity, it detects low-abundance immune mediators often missed by conventional platforms, delivering a deep, single-run immune profile for translational and clinical studies to understand disease heterogeneity, progression, and therapeutic response. Apply to power your research with comprehensive immune profiling.
Disease Pathogenesis: Elucidate mechanisms of inflammation and identify potential therapeutic targets. By measuring multiple proteins simultaneously, gain insights into complex interactions, signaling pathways, and regulatory mechanisms involved in disease processes.
Biomarker Discovery: Identify new biomarkers associated with inflammation by measuring a wide range of proteins simultaneously in different disease states and compare them to healthy controls.
Drug Development and Clinical Trials: Evaluate the effects of potential therapeutic agents on specific protein targets related to inflammation and assess their efficacy in preclinical and clinical studies.
Diagnostic Development: Measure specific protein markers known to be associated with the presence and severity of diseases and differentiate between different subtypes or stages of a particular disease.
Apply by October 15, 2026:
Terms and Conditions
1. Sponsor and Acceptance
Alamar Biosciences, Inc., 47071 Bayside Parkway, Fremont, California 94538, USA (“Alamar”) is the sole sponsor of the NULISAseq™ Immune 340 Grant Program (the “Program”). No purchase or payment is necessary to enter or to win.
By submitting an application, each applicant (“Applicant”) agrees to these Terms and Conditions (these “Terms”) and to the decisions of Alamar and its judges, which are final and binding on matters of eligibility and selection. Any additional Program details published at alamarbio.com form part of these Terms.
2. Eligibility
An Applicant must be at least 18 years of age and must be actively enrolled at, or employed in a research capacity by, an academic institution, hospital, or other research organization. An Applicant must have access to samples suitable for the proposed project, together with the rights and approvals necessary to provide them to Alamar, and must have or reasonably expect to obtain institutional authorization to accept the award.
Employees, officers, directors, and contractors of Alamar and its affiliates, members of their immediate families, and persons living in the same household as any such individual are not eligible.
The Program is void where prohibited or restricted by law. Alamar will not make an award to any person or entity located in, or subject to the jurisdiction of, a country or region subject to comprehensive U.S. economic sanctions, or identified on a U.S. government restricted-party list.
3. The Award
Each grant made under the Program is an “Award,” and the person to whom an Award is made is a “Recipient.”
4. How to Apply, Selection, and Timeline
Applications must be submitted using the form above and must include project/study abstract, summary of the sample cohort, proposed timeline, and institutional affiliation. Submissions must be received by 11:59 PM Pacific Time on Thursday, October 15, 2026. Applications that are incomplete or late will not be considered, and Alamar is not responsible for applications that are lost, delayed, misdirected, or not received.
Applications will be evaluated by judges selected by Alamar, which may include Alamar employees and external scientific advisors under obligations of confidentiality, on the basis of: access to banked samples with associated clinical annotations; ability to complete the project within six (6) months of delivery of the data; and scientific merit and the potential for publication in a high-impact peer-reviewed journal.
Recipients will be notified by email on or about 3 weeks following the close of the Program, and all Applicants will receive confirmation that their submission was received. A Recipient must respond within 10 business days and complete the documentation Alamar reasonably requires before services begin, which may include a work plan or service agreement, a material transfer agreement, and written institutional approval. Failure to respond, ineligibility, or failure to complete that documentation may result in disqualification and selection of an alternate.
CSO
Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.
CFO
Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition. He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.